We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seelos Therapeutics Inc | NASDAQ:SEEL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0018 | -0.20% | 0.9051 | 0.9045 | 0.979 | 1,166 | 13:00:01 |
|
PROSPECTUS
|
| |
|
| | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 17 | | | |
| | | | 19 | | | |
| | | | 24 | | | |
| | | | 24 | | | |
| | | | 24 | | | |
| | | | 24 | | | |
| | | | 25 | | |
|
Product
|
| |
Indication
|
| |
Development Phase
|
| |
Development Status
|
|
|
SLS-002
Intranasal Racemic Ketamine |
| |
Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD)
|
| |
Phase II
|
| |
Completed open-label patient enrollment and announced the initial topline data from Part 1 of the proof-of-concept study on May 17, 2021; enrollment of Part 2 of a Phase II study closed in June 2023; topline data for Part 2 announced on September 20, 2023
|
|
|
SLS-005
IV Trehalose |
| |
Amyotrophic Lateral Sclerosis (ALS)
|
| |
Phase II/III
|
| |
Completed enrollment of final participants in February 2023 in the registrational study; data readout expected in late 2023
|
|
| | | |
Spinocerebellar Ataxia (SCA)
|
| |
Phase IIb/III
|
| |
In October 2022, we announced dosing of the first participant in the registrational study; enrollment of additional patients temporarily paused on March 29, 2023
|
|
| | | |
Huntington’s Disease (HD) and Alzheimer’s Disease (AD)
|
| |
Phase II
|
| |
Obtaining biomarker activity
|
|
|
SLS-004
Gene Therapy |
| |
Parkinson’s Disease (PD)
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing; in December 2022, we announced partial results from a study demonstrating downregulation of α-synuclein; currently analyzing data while temporarily pausing additional spend
|
|
|
Product
|
| |
Indication
|
| |
Development Phase
|
| |
Development Status
|
|
|
SLS-007
Peptide Inhibitor |
| |
Parkinson’s Disease (PD)
|
| |
Pre-IND
|
| |
Preclinical study completed and analysis of the results ongoing; next steps for development of this program will be decided in concert with SLS-004 results and readouts, as both target the same pathway upstream; temporarily pausing additional spend
|
|
|
SLS-009
|
| |
HD, AD, ALS
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing
|
|
| | |
Shares Beneficially Owned
Prior to the Offering(1) |
| |
Maximum Number of
Shares of Common Stock to be Offered Pursuant to this Prospectus |
| |
Shares Beneficially
Owned After the Offering(1) |
| | | | | | | |||||||||||||||||||||
Name
|
| |
Number
|
| |
Percentage
|
| |
Number
|
| |
Percentage
|
| | | | | ||||||||||||||||||||
Lind Global Asset Management V, LLC(2)
|
| | | | 3,732,035(3) | | | | | | 2.87% | | | | | | 1,000,000 | | | | | | 2,732,035 | | | | | | 2.10% | | | | | ||||
Entities associated with Empery Asset Management LP(4)
|
| | | | 13,423,897(4) | | | | | | 9.99% | | | | | | 4,000,000 | | | | | | 13,423,897 | | | | | | 9.99% | | | | |
1 Year Seelos Therapeutics Chart |
1 Month Seelos Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions